Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Positive Phase III data for Recarbrio (imipenem/cilastatin/relebactam) have been announced by New Jersey, USA-based drugmaker Merck & Co. 6 May 2020
Biotechnology
Amgen’s Otezla (apremilast), a drug divested by Celgene ahead of its acquisition by Bristol-Myers Squibb, could soon be approved in a new indication after the presentation of new data. 6 May 2020
Biotechnology
The submission of additional information, upon the request of the US regulator, has delayed the action date for Bristol-Myers Squibb’s CAR-T cell candidate lisocabtagene maraleucel (liso-cel). 6 May 2020
Biotechnology
US drugmaker Alexion Pharmaceuticals fared better in its revenue and adjusted earnings figures in the first quarter of 2020, compared to a year earlier. 6 May 2020
Biotechnology
Pandemic-based stockpiling among people with diabetes helped lift revenues beyond analysts’ expectations for Denmark’s biggest drugmaker, Novo Nordisk. 6 May 2020
Biotechnology
Swiss drugmaker Ferring and its Rebiotix subsidiary have announced a world first with a microbiome-based therapy. 6 May 2020
Biotechnology
Following a couple of active M&A years, USA-based Alexion Pharmaceuticals has now reached a definitive agreement to acquire Portola Pharmaceuticals, a commercial-stage biotech focused on blood-related disorders. 6 May 2020
Biotechnology
Shares of US biotech Akebia Therapeutics were up more than 35% at $11.72 by early afternoon today, after it announced positive top-line results from INNO2VATE, the first of its two global Phase III cardiovascular outcomes programs. 5 May 2020
Biotechnology
Investors in Regeneron could afford a rare smile in these difficult times, as the company’s first quarter results came in on Tuesday, sending shares 7% higher by midday. 5 May 2020
Biotechnology
Positive top-line data for a pivotal, single-arm, open-label trial of PD-1 inhibitor Libtayo (cemiplimab) in patients with advanced basal cell carcinoma (BCC) who had progressed on or were intolerant to prior hedgehog pathway inhibitor (HHI) therapy were announced today, marking the second non-melanoma skin cancer for which the drug has demonstrated first-in-class data. 5 May 2020
Biotechnology
A new collaboration between Shanghai’s Junshi Biosciences and Eli Lilly will seek to develop novel antibodies to treat and prevent COVID-19. 5 May 2020
Biotechnology
Privately-held pharma and diagnostics firm Menarini Group has announced a definitive agreement to acquire USA-based Stemline Therapeutics. 5 May 2020
Biotechnology
A collaboration in COVID-19 between immunology specialist Vir Biotechnology and Alnylam Pharmaceuticals has begun to bear fruit. 5 May 2020
Biotechnology
The European medicines regulator has OK’d a label update for AstraZeneca’s Lokelma (sodium zirconium cyclosilicate), to include people with hyperkalemia on stable hemodialysis. 5 May 2020
Biotechnology
A new collaboration targeting rare heart diseases has been formed between California’s BioMarin Pharmaceutical and Swiss gene therapy firm DiNAQOR. 4 May 2020
Biotechnology
Privately-held Canadian biotech AbCellera Biologics has received a commitment of up to C$175.6 million ($125 million) in support from the government under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to expand efforts related to the discovery of antibodies for use in drugs to treat COVID-19, and to build technology and manufacturing infrastructure for antibody therapies against future pandemic threats. 4 May 2020
Biotechnology
French drugmaker Ipsen has bought an option on an oncology program from Montreal-based biotech group, IRICoR. 4 May 2020
Biotechnology
Research from the non-profit EURORDIS-Rare Diseases alliance shines a light on the impact of the COVID-19 pandemic on people living with rare diseases. 3 May 2020
Biotechnology
On May 1, the US Food and Drug Administration approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. 2 May 2020
Biotechnology
US pharma major AbbVie closed trading up modest a 0.8% at $82.84 on Friday, despite reporting first-quarter 2020 financials that beat Wall Street predictions. 2 May 2020
All news
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze